DDIT3 and diffuse large B-cell lymphoma: Although preferential activity with bortezomib for cases with the refractory ABC/non-GCB subtype was suggested early on [8], recently published data concerning frontline VR-CAP do not indicate a significant difference with R-CHOP in the non-GCB type DLBCL [9], and the differential efficacy remains controversial.